Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Pathol Biol (Paris) ; 33(1): 50-4, 1985 Jan.
Article in French | MEDLINE | ID: mdl-3871932

ABSTRACT

Genetic susceptibility (HLA types), clinical and pathological findings, amount of acetylcholine receptor antibodies and T lymphocyte subpopulations were studied in 63 patients with Myasthenia Gravis (MG). The frequency of HLA-DR5 was increased among patients (0.50 versus 0.23 in controls, pc less than 0.01, relative risk 3.3) and that of HLA-DR3 previously described as associated with MG was slightly increased (0.31 versus 0.20 in controls). The relative frequencies of two T cell subpopulations (T4 helper and T8 suppressor/cytotoxic lymphocytes) were normal in HLA-DR5 positive patients while the ratio T4/T8 was increased in other MG patients, who were HLA-DR3 (p less than 0.005). The high rate was due to an increase in the absolute number of T4 lymphocytes (p less than 0.001). HLA-DR3 patients were mostly women with early onset of a severe form of the disease, marked by the presence of thymic follicular lymphoid hyperplasia. A third genetic susceptibility to this disease was recently described in patients treated with D-penicillamine, the antigenic frequency of HLA-Bw35, DR1 is significantly increased. These 3 types of association between HLA and myasthenia gravis can be related to three different physiopathological mechanisms: the first two are probably linked to individual immunity (inductor/suppressor disequilibrium), in the third association, the mechanism is immunopharmacological.


Subject(s)
HLA Antigens/analysis , Myasthenia Gravis/immunology , Adult , Disease Susceptibility , Female , HLA Antigens/immunology , HLA-B8 Antigen , HLA-C Antigens , HLA-DR5 Antigen , HLA-DR7 Antigen , Histocompatibility Antigens Class II/analysis , Humans , Male , Myasthenia Gravis/genetics , T-Lymphocytes/classification
SELECTION OF CITATIONS
SEARCH DETAIL
...